Overview

British Society for Rheumatology paediatric and adolescent guidance notes are designed to support those working in paediatric and adolescent care.

Guidance notes are developed to support professionals in several ways, including encouraging a consistent approach to care delivery, promoting the effective use of resources and reducing the likelihood of inappropriate care. Overall, the most important potential benefit is the improvement of the quality of care received by the patient and better health outcomes.

Treatment approaches can vary between clinicians and these guidance notes provide an opportunity to set out best practice based on current evidence or expert consensus. They help to increase consistency in practice and promote the highest standards of care.

Recommendations provided are intended to improve the quality of clinical decision-making, but each individual circumstance may be different and this should be taken into consideration. These notes are subject to revision; we welcome your feedback on any of the documents below.

Please note: many of these documents were produced in collaboration with other organisations, details of which can be found within each specific guidance note.

Methotrexate guidance

Methotrexate guidance for paediatric and adolescent rheumatology health professionals

Find out more


Tocilizumab guidance

Tocilizumab guidance for paediatric and adolescent rheumatology health professionals

Find out more


Adalimumab guidance

Adalimumab guidance for paediatric and adolescent rheumatology health professionals 

Find out more


Standards of care for JIA

A statement of minimum standards of care required by children and young people with JIA

Find out more